Monthly Archives: June 2010

Hamburg Delivers DIA Keynote

By George Koroneos | Published: June 14, 2010
FDA Commissioner Margaret Hamburg delivered this year’s keynote speech in front of a packed room of pharma and bioscience personnel at the 46th annual meeting of the Drug Information Association, which opened Monday morning. Hamburg started her speech by explaining how her earliest goal as FDA chief was to build the field of regulatory [...]
Posted in Events, FDA | Tagged , , , | 2 Comments

Elmendorf Refuses to Go Quietly Into the Night of HCR

By Pharm Exec | Published: June 9, 2010
Guest Blog by Tom Norton of NHD Smart Communications. You can reach him at tnorton@nhdcomm.com. Amidst all the gurgling of oil last week(bad! bad! bad!), a competing thunderstorm of words erupted as Doug Elmendorf, Director of CBO, had the temerity to revisit the real costs of the new HCR law. Addressing something that, for whatever reason, [...]
Posted in Guest Blog | Tagged , , , , , , , | 2 Comments

Avastin Study Shows Promising Data for Cancer Patients

By George Koroneos | Published: June 8, 2010
Genentech released the results of its Phase III Avastin study showing that women that take the ovarian cancer treatment in tandem with chemotherapy had a 39 percent improvement in the likelihood of living longer without the disease worsening than patients being treated with just chemotherapy. The data was released at the annual meeting of American Society [...]
Posted in R&D | Tagged , , , , | Leave a comment

Murky EU Definition of ‘Counterfeit’ Set to Hit Pharma

By Julian Upton | Published: June 8, 2010
Paul McClenaghan looks at how the UK high court’s recent decision regarding a shipment of fake Nokia phones could have serious ramifications for the transit of pharmaceuticals in Europe. Recent complaints made by Brazil and India to the World Trade Organization regarding the seizure of generic pharmaceutical products in transit through the European Union illustrate the [...]
Posted in Strategy | Leave a comment

Johnson & Johnson Slammed Over Manufacturing Practices, Phantom Recall

By Oriana Schwindt | Published: June 2, 2010
In 1982, Johnson & Johnson garnered an enduring amount of goodwill when, seemingly without any thought of lost profit, it immediately yanked Tylenol from the shelves nationwide after learning someone was slipping cyanide into bottles in Chicago. The company’s sure and swift PR response became the model for crisis management for the corporate world. But in [...]
Posted in Corporate Responsibility | Tagged , , , , , , , , , , | 3 Comments